Mark L. Fuerst
Staff Correspondent
Triple directing-acting combination treats decompensated liver disease
A combination of three drugs successfully treats HCV-infected patients with advanced liver disease.
Liver transplant recipients with HCV fare well under drug combo
Hepatitis C virus infection in liver transplant recipients can be treated with ledipasvir and sofosbuvir without ribavirin.
Study: 12 weeks therapy combination cures virtually all HCV patients
A shorter, triple DAA therapy combination is not superior to 12 weeks of sofosbuvir plus velpatasvir in chronic HCV patients, according to researchers.
HBV reactivation with direct acting antivirals for HCV is highly manageable
New study indicates early recognition of HBV-HCV co-infection can lead to prompt treatment of HBV reactivation.
Study: DAA all-oral combination successful in treating hepatitis C
Early data shows promise in “real-world” effectiveness.
Real-world DAA therapy shows gains in community setting
Physicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.
DAAs do not increase risk of hepatic decompensation in HCV patients
Researchers say theirs is first national study with a large population to examine possible link.
DAA therapy effective in advanced liver disease in real-world study
All-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients.
DAAs aid treatment of hepatitis C patients with cancer
Direct-acting antiviral agents can be safely administered with chemotherapy in patients with hepatitis C virus, according to new research.
DAA treatment restricted for Canadian hepatitis C patients
Patients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers.